Genepharm
Genepharm is a privately held Greek pharmaceutical company, founded in 1967 and headquartered in Pallíni, focused on the development, manufacturing, and marketing of generic pharmaceutical products.
- Company typePrivate
- Founded1967
- HeadquartersPallíni, Greece
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genepharm does
Genepharm is a privately held Greek pharmaceutical company headquartered in Pallíni, Greece, founded in 1967. According to its stated firmographic description, the company's focus is on the development, manufacturing, and marketing of generic pharmaceuticals, placing it within the European off-patent medicines segment.
The company operates as a vertically integrated generics producer, combining in-house development, manufacturing, and commercial distribution functions. As a generic-pharma manufacturer, its commercial activity depends on regulatory approvals (principally EMA and Greek national authorities), bioequivalence demonstration against reference listed drugs, and an established product portfolio typical of long-tenured generics firms. The input data does not disclose the specific therapeutic areas, molecule count, dosage forms, manufacturing capacity, or facility footprint.
Business model mechanics — pricing, customer mix, channel structure, export presence, and contract terms — are not described in the available data, and the company's website (genepharm.com) returned only a loading/verification page rather than substantive content during data collection. No headcount, revenue, funding history, ownership, management, partnership, or product-launch information is available in the input. As a result, while Genepharm's core function as a Greek generic-pharma developer/manufacturer/marketer is verifiable, any deeper characterization of scale, commercial reach, or competitive position would require primary disclosure that is not present in the supplied material.
Genepharm firmographics
Firmographics- Name
- Genepharm
- Website
- https://genepharm.com
- Company type
- Private
- Founded year
- 1967
- Short description
- Genepharm is a privately held Greek pharmaceutical company, founded in 1967 and headquartered in Pallíni, focused on the development, manufacturing, and marketing of generic pharmaceutical products.
- Ownership category
- akta.pro rank
Genepharm industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
Keywords
Where Genepharm is headquartered
LocationHeadquarters
- HQ city
- Pallíni
- HQ country
- Greece
- HQ region
- Europe
Markets served
Genepharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Genepharm product offering
Product offeringCore offering
Genepharm is focused on the development, manufacturing and marketing of quality generic pharmaceuticals. The company produces off-patent drug formulations for downstream healthcare buyers. Its operations are centered in Pallíni, Greece, where it has been active since 1967.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Pharmaceuticals
Companies that use Genepharm
Customer profileIdeal customer profiles1 record
Genepharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Genepharm competitors and assessment
Company assessmentDirect peers
- Pharmathen: Greek-headquartered generic pharmaceutical developer and manufacturer with a similar vertically integrated generics model serving EU markets, making Pharmathen the closest geographic and product analog to Genepharm.
- ELPEN Pharmaceutical: Greek pharmaceutical manufacturer focused on generics and branded generics, sharing both Genepharm's home market and its development-plus-manufacturing orientation within the EU generics landscape.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with broad small-molecule generics portfolios across EU markets; relevant as the dominant incumbent shaping competitive dynamics for EU-based generic players like Genepharm.
- Sandoz: Novartis-spin-off generics and biosimilars business and one of the largest global generics competitors; comparable to Genepharm in core small-molecule generics and a benchmark for EU generics economics.
- Viatris: Formed by the Mylan-Upjohn merger, Viatris is a major global generics and off-patent pharmaceuticals company with deep EU distribution, serving as a broad incumbent peer for an EU-based generics manufacturer.
- STADA Arzneimittel: European-focused generics and consumer healthcare company with established small-molecule generics franchises across Germany, CEE, and broader EU — closely comparable to Genepharm on geography and product scope.
Regional players
- KRKA: Slovenian-headquartered generics manufacturer with a Central and Eastern European distribution footprint; comparable to Genepharm as a Central-Southern European vertically integrated generic player.
- Gedeon Richter: Hungarian pharmaceutical company with a significant generics business across CEE and Western Europe; comparable to Genepharm in operating from a smaller EU country while serving broader European generics markets.
- Polpharma: Polish generics manufacturer with broad EU generics presence and vertically integrated operations; comparable to Genepharm as a Central European generic pharma producer competing for the same EU tender and distribution channels.
Emerging players
- Alvotech: Icelandic-headquartered specialty generics and biosimilars developer; relevant as a smaller EU-rooted player pushing into higher-value generic/biosimilar segments that Genepharm could pursue as an upgrade path.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat4 records
Key risks4 records
Key highlights4 records
Customer concentration
Genepharm social profiles
Digital presenceGenepharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genepharm leadership team
Management profileNumber of profiles
Genepharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genepharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genepharm
What does Genepharm do?
Genepharm is focused on the development, manufacturing and marketing of quality generic pharmaceuticals. The company produces off-patent drug formulations for downstream healthcare buyers. Its operations are centered in Pallíni, Greece, where it has been active since 1967.
When was Genepharm founded?
Genepharm was founded in 1967.
Where is Genepharm based?
Genepharm is headquartered in Pallíni, Greece, in the Europe region.
Who are Genepharm's main competitors?
Direct peers on record are Pharmathen and ELPEN Pharmaceutical. Broad incumbents are Teva Pharmaceutical Industries, Sandoz, Viatris and STADA Arzneimittel. Regional players are KRKA, Gedeon Richter and Polpharma. Alvotech is listed as an emerging player.
Does Genepharm have an API?
No public API is recorded for Genepharm.
What industry is Genepharm in?
Genepharm's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.